CUE Form 3: Usman Azam Listed as CEO and Director; Zero Holdings

Rhea-AI Filing Summary

Usman Azam filed a Form 3 reporting his relationship to Cue Biopharma, Inc. (CUE) as both a director and the Chief Executive Officer. The form shows the date of event as 09/29/2025 and states that no securities are beneficially owned by the reporting person as of the filing. The filing was executed by an attorney-in-fact on 10/02/2025 and includes an exhibit: Exhibit 24.1 - Power of Attorney.

Positive

• Reporting identifies Usman Azam as both Chief Executive Officer and director of Cue Biopharma
• Form 3 filed and includes Exhibit 24.1 - Power of Attorney, showing proper execution

Negative

• No securities beneficially owned by the reporting person as of 09/29/2025

Insights

Corporate Governance Analyst

Form 3 discloses a CEO/director relationship but reports zero holdings as of 09/29/2025.

The filing confirms Usman Azam holds positions as both a director and Chief Executive Officer of Cue Biopharma (CUE). It explicitly states no securities are beneficially owned by him at the time of the report, and includes a Power of Attorney exhibit authorizing the signature.

This disclosure is factual and narrow: it documents status and ownership at a point in time without additional transaction, grant, or transfer details.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Azam Usman

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/29/2025

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Usman Azam by Michael Meluzio, attorney-in-fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Cue Biopharma (CUE) disclose?

The Form 3 discloses that Usman Azam is a director and the Chief Executive Officer and that he beneficially owns no securities as of 09/29/2025.

When is the event date and filing date on the CUE Form 3?

The event date reported is 09/29/2025 and the Form 3 was signed/executed on 10/02/2025 by an attorney-in-fact.

Does the filing indicate any derivative or non-derivative holdings for CUE?

No. The filing explicitly states no securities are beneficially owned and lists no derivative or non-derivative holdings.

Was the Form 3 filed by more than one reporting person?

No. The filing indicates it was a Form filed by One Reporting Person.

Is there an authorization included with the Form 3 for the signature?

Yes. The filing references Exhibit 24.1 - Power of Attorney and shows the signature executed by an attorney-in-fact.